DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

GSK1120212+GSK2141795 for Cervical Cancer

Phase 2

Terminated

Conditions: Cervical Cancer

Interventions: Drug: GSK1120212 (trametinib)
Drug: GSK2141795

First Posted Date: 2013-10-08

Last Posted Date: 2019-05-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT01958112

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

Not Applicable

Completed

Conditions: Monoclonal Gammopathy of Undetermined Significance
Smoldering Multiple Myeloma

Interventions: Behavioral: Relaxation Response Resiliency Program (3RP)

First Posted Date: 2013-10-07

Last Posted Date: 2017-03-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 93

Registration Number: NCT01955395

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Enzalutamide

First Posted Date: 2013-09-16

Last Posted Date: 2022-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 67

Registration Number: NCT01942837

Locations: 🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States
🇺🇸
University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 2 locations

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Phase 1

Active, not recruiting

Conditions: Chronic GVHD
Complications of Organ Transplant Stem Cells
Chronic Graft Versus Host Disease

Interventions: Other: Treg-enriched infusion
Drug: Interleukin-2

First Posted Date: 2013-09-09

Last Posted Date: 2025-02-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01937468

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Phase 1

Completed

Conditions: Brain Metastases From HER2 and Breast Cancer
Advanced HER2-positive Breast Cancer

Interventions: Drug: ARRY-380 Twice Daily Dosage
Drug: ARRY-380 Once Daily
Drug: Trastuzumab

First Posted Date: 2013-08-13

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 41

Registration Number: NCT01921335

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Pertuzumab
Drug: Trastuzumab
Drug: eribulin

First Posted Date: 2013-07-31

Last Posted Date: 2018-12-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT01912963

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Early Phase 1

Completed

Conditions: Inflammatory Breast Carcinoma

Interventions: Drug: 89Zr-bevacizumab
Procedure: FDG-PET/CT
Procedure: MRI scan
Procedure: Tumor biopsies

First Posted Date: 2013-07-10

Last Posted Date: 2019-12-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01894451

Locations: 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

Early Phase 1

Terminated

Conditions: T-Cell Lymphoma
Relapsed T-Cell Lymphoma
Refractory T-Cell Lymphoma

Interventions: Drug: PEG-L-asparaginase
Drug: Dexamethasone acetate

First Posted Date: 2013-06-17

Last Posted Date: 2017-03-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01878708

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Device: Multiparametric MRI
Procedure: Prostate biopsy

First Posted Date: 2013-05-21

Last Posted Date: 2023-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT01858688

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

iCAT for Recurrent/Refractory/HR Solid Tumors

Completed

Conditions: Wilms Tumor
Sarcoma
Neuroblastoma
Pediatric Solid Tumor

First Posted Date: 2013-05-15

Last Posted Date: 2015-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT01853345

Locations: 🇺🇸
Children's National Medical center, Washington, District of Columbia, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy